Australian Generics Approval Reform Is Opportunity For International Work-Sharing On Non-Biological Complex Drugs
Executive Summary
Plans to streamline the approval of generic medicines in Australia must include measures to ensure that safe and effective similar versions of non-biological complex medicines are available.
You may also be interested in...
Messy Rules For Non‐Biological Complex Drugs Under Fire
Calls are mounting for the EU to make the centralized procedure mandatory for follow-on versions of non‐biological complex drugs and for better regulatory alignment with the US and other countries.
Australia Considers Changes To Bioequivalence Requirements For Foreign Comparators
Changing Australian requirements on showing equivalence with an overseas reference product used in bioequivalence studies, and introducing a new early scientific advice service for biowaiver proposals, are among key proposals made by the Therapeutic Goods Administration as part of reforms in the generic medicines sector.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.